MOTIVATION LETTER The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, emerged from a single observation: existing addiction pharmacotherapies target dopamine receptors or metabolic enzymes, but none address the memory consolidation step that transforms a drug experience into a compulsive drive. My three sole-authored preprints on OSF and Zenodo formalize this gap mathematically. The foundational paper (OSF 10.17605/OSF.IO/KG7B5) defines the CCT as the minimum simultaneous activation of D1, NMDA, and beta-arrestin pathways required for reward-memory encoding. The formal mathematical specification (OSF 10.17605/OSF.IO/EMY4U) expresses this as a system of coupled ODEs solved via RK45. The Bayesian population dynamics paper (Zenodo 10.5281/zenodo.20492472) validates the model against simulated clinical trial data: encoding probability drops from 0.855 to 0.122, an 85.8% reduction, with super-additivity of 12.8 percentage points across the three targets. All five pre-registered hypotheses H1 through H5 were confirmed. This work has been endorsed by Kent Berridge at the University of Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at New York University. Gershman provided my arXiv endorsement. A provisional patent on the CCT core architecture is scheduled for Q3 2026. I am an independent researcher based in Lagos, Nigeria, with a B.Pharm from the University of Ibadan (CGPA 5.1/7.0, German equivalent 1.9) and a PCN pharmacist license. I currently serve as National Product Manager at Synthcare. My computational toolkit includes Python with scipy, numpy, PyMC for Bayesian MCMC, ODE/RK45 solvers, topological data analysis via Ripser and Gudhi, NEURON and Brian2 for neural simulation, AlphaFold and RDKit for structural biology, and GROMACS and AutoDock for molecular dynamics. I built three platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions with persistent homology and bipartite simplicial complexes including a hERG cardiotoxicity MVP, and GATE for BCI neural-stimulation safety evaluation, released under Apache 2.0. The Silvio O. Conte Centers programme funds basic neuroscience and translational mental health research at a center scale. I cannot apply as a lead applicant because the programme requires a U.S.-based institution. However, my CCT model offers a computational core that could anchor a Conte Center application led by a U.S. collaborator such as Kent Berridge at Michigan. The model provides a mathematically specified, pharmacologically testable framework for reward-memory encoding that bridges molecular pharmacology, systems neuroscience, and computational psychiatry. My position in Nigeria adds a global health dimension: addiction burden in sub-Saharan Africa is rising, yet no computational pharmacology framework has been developed from within the continent. I seek a collaborator willing to include me as a key international partner, contributing the CCT model, the Bayesian clinical trial architecture, and the LMIC perspective that strengthens the center's innovation and global impact. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a specific gap in addiction neuroscience: the molecular mechanism by which a drug experience becomes a consolidated reward memory. Current models treat dopamine signaling, NMDA-dependent plasticity, and beta-arrestin recruitment as separate pathways. The CCT model posits that these three pathways must cross a simultaneous activation threshold for memory encoding to occur. Below this threshold, the experience is processed but not consolidated into long-term reward memory. Above it, encoding proceeds with probability approaching 1. The mathematical formulation is a system of three coupled ordinary differential equations representing D1 receptor activation, NMDA receptor calcium flux, and beta-arrestin scaffolding dynamics. Each equation includes a Hill coefficient for cooperativity, a decay term for signal termination, and a coupling parameter representing cross-pathway potentiation. The threshold condition is a product of the three activation states exceeding a critical value. I solved this system using RK45 integration in Python with scipy.integrate.solve_ivp, scanning a parameter space of 10,000 combinations of agonist concentrations and receptor densities. The ODE solutions were then embedded in a Bayesian population model using PyMC with Hamiltonian Monte Carlo sampling, four chains of 5,000 samples each, and R-hat convergence diagnostics below 1.01 for all parameters. The results: baseline encoding probability of 0.855 under single-target activation (e.g., D1 agonist alone). Triple-target activation at the CCT reduces encoding probability to 0.122, an 85.8% reduction. The super-additivity effect is 12.8 percentage points, meaning the triple combination outperforms the sum of pairwise combinations. All five pre-registered hypotheses were confirmed: H1 (triple activation reduces encoding below single activation), H2 (super-additivity exists), H3 (threshold is nonlinear), H4 (decay rates modulate threshold), H5 (population heterogeneity shifts threshold distribution). The clinical trial architecture in the third preprint designs a Bayesian adaptive trial with 200 participants per arm, three active arms (single, dual, triple target) and placebo, with reward-memory encoding measured via cue-induced craving in fMRI and behavioral choice tasks. The primary endpoint is encoding probability at 24 hours post-exposure. The trial uses response-adaptive randomization with a Thompson sampling allocation ratio updated every 20 participants. The Bayesian posterior probability of superiority for the triple arm exceeds 0.95 at the interim analysis. For a Conte Center, the CCT model would serve as the computational core that integrates molecular pharmacology, systems neuroscience, and clinical translation. The model generates testable predictions: specific drug combinations that should prevent memory encoding, time windows for intervention, and biomarkers of threshold crossing. The platforms I built support this integration. IMPRINT screens addiction liability by computing CCT parameters from receptor expression profiles. TOPOLOGIX uses persistent homology on bipartite simplicial complexes of drug-protein interaction networks to identify off-target effects that could disrupt or enhance the CCT. GATE evaluates neural-stimulation safety by modeling how BCI-induced activity modulates the threshold. The LMIC perspective is not cosmetic. Addiction treatment in Nigeria relies on abstinence-based models with no pharmacotherapy for memory disruption. The CCT framework could be deployed as a low-cost screening tool using IMPRINT on standard clinical data, then targeted with generic drugs that modulate D1, NMDA, and beta-arrestin pathways. This is a testable hypothesis that a Conte Center could evaluate in a cross-cultural trial design. COLLABORATOR LETTER DRAFT Dear Kent, I am writing to propose a collaboration on a Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research application. My CCT model provides a mathematically specified computational core for reward-memory encoding prevention in addiction. The model is validated by ODE/RK45 and Bayesian MCMC, showing 85.8% reduction in encoding probability with super-additivity of 12.8 percentage points. All five pre-registered hypotheses are confirmed. Three sole-authored preprints are on OSF and Zenodo, and a review article is under review at Neuroscience and Biobehavioral Reviews. I cannot lead a Conte Center application because I am based in Lagos, Nigeria, without a U.S. institutional affiliation. However, I can contribute the CCT model as the computational core of a center you lead. I bring the full mathematical specification, the Bayesian clinical trial architecture, the IMPRINT screening platform, the TOPOLOGIX TDA pipeline, and the GATE safety evaluation tool. I also bring a perspective from a region where addiction pharmacotherapy is essentially absent, which strengthens the center's global health impact. My collaborators include Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. Gershman provided my arXiv endorsement. A provisional patent on the CCT core architecture is scheduled for Q3 2026. I am available to discuss how the CCT model fits your existing research program and what resources would be needed to include me as a key international collaborator. I can travel to Michigan for meetings and am open to co-supervising students or postdocs on the computational components. Respectfully, Eniola Ayodele Olutogun Independent researcher, Lagos / ZYCO ORCID: 0009-0001-9272-6735 GitHub: github.com/AmunRaPtah zyco.org CHECKLIST - [ ] Confirm that Kent Berridge is willing to serve as lead PI and include CCT as computational core - [ ] Draft a letter of support from Berridge confirming the collaboration and resource commitment - [ ] Verify that Conte Center programme allows international collaborators as co-investigators (not just consultants) - [ ] Prepare a one-page summary of CCT model with key equations and validation results for the application - [ ] Gather letters of endorsement from Gershman, Daw, and Mattar - [ ] Update ORCID record with all three preprints and the review article under review - [ ] Secure provisional patent filing receipt for CCT core architecture - [ ] Prepare a budget justification for international travel, computational resources, and potential subaward to a Nigerian institution - [ ] Verify that the Conte Center deadline allows sufficient time for collaborator negotiations - [ ] Confirm that the programme does not require U.S. citizenship or permanent residency for collaborators EDITOR NOTES - Eligibility risk: The Conte Center programme explicitly requires a U.S.-based institution as the applicant. Eniola cannot apply as lead. The collaborator letter assumes Berridge agrees. This must be confirmed before any submission. - Fact verification: The Bayesian population dynamics paper on Zenodo (10.5281/zenodo.20492472) should be checked for correct DOI and that it is publicly accessible. The review article under review at Neuroscience and Biobehavioral Reviews should be confirmed as still under review and not rejected. - Gap: The profile does not specify whether Eniola has prior experience with NIH grant mechanisms or federal funding compliance. If she is included as a collaborator on a U.S. grant, she may need to complete NIH training on responsible conduct of research and human subjects protections. This should be addressed in the application or in a separate letter.